Clinical trials
Acute Lymphoblastic Leukemia clinical trials
Below are recruiting acute lymphoblastic leukemia clinical trials, each written for real people, not researchers. We’re tracking 398 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04684147RecruitingPhase 2
CNCT19 cell therapy for relapsed or refractory ALL
This Phase 2 study tests an infusion of modified immune cells (CNCT19) in people with acute lymphoblastic leukemia (ALL) that has come back or did not respond to treatment. It may help by targeting leukemia cells that have a specific marker called CD19.
Beijing, Beijing MunicipalityAges 18–65 - NCT04726241RecruitingPhase 1/Phase 2
Testing blood and bone marrow samples in young leukemia patients
This trial looks at blood and bone marrow samples from children and teens whose leukemia has come back or is hard to treat. The goal is to better understand the disease and guide future options for these patients.
Birmingham, AlabamaAges Up to 22 years - NCT04746209RecruitingPhase 2
Blinatumomab after transplant for high-risk B-ALL patients
This trial tests blinatumomab, an immune therapy, in young people with B-cell acute lymphoblastic leukemia (B-ALL) after their transplant or when they are getting ready for transplant. The goal is to lower the chance of the leukemia coming back by targeting remaining leukemia cells.
Milwaukee, WisconsinAges Up to 25 years - NCT04747912RecruitingPhase 2
Chemotherapy-free early treatment for Ph+ ALL using inotuzumab
This Phase 2 trial tests a treatment strategy for newly diagnosed Ph+ B-cell acute lymphoblastic leukemia (ALL) that avoids traditional chemotherapy during the early “induction” phase, using inotuzumab ozogamicin instead. If it works, it could help control the leukemia while reducing exposure to chemotherapy early on.
Chicago, IllinoisAges 18 years+ - NCT04872478RecruitingPhase 1
Early-phase drug safety and dosing study for relapsed blood cancers
This Phase 1 trial tests MRX-2843 in teenagers and adults whose leukemia has come back or did not respond to prior treatment. The main goals are to find safe dosing and learn how the body processes the drug.
Atlanta, GeorgiaAges 12 years+ - NCT04881240RecruitingPhase 1
Donor-made memory T-cell therapy for hard-to-treat leukemia
This Phase 1 study tests an immune-cell therapy made from a matched donor to treat relapsed or refractory CD19-positive leukemia. It may help patients who have limited options, especially those who cannot receive the standard donor-cell or self-made (autologous) CD19 CAR T-cell therapy.
Memphis, TennesseeAges Up to 21 years - NCT04888741RecruitingPhase 2
Trial testing reduced immune T cells before stem cell transplant
This Phase 2 trial looks at a transplant approach that reduces harmful immune cells (T cells) before or during an allogeneic stem cell transplant. It may help lower the risk of transplant complications while still letting the donor immune system fight the blood cancer.
Cardiff, WalesAges 16–70 - NCT05735717RecruitingPhase 2
T-cell transplant using depleted receptors for blood cancers
This Phase 2 study tests a specialized stem cell transplant that removes certain immune “T-cell” receptors to help treat blood cancers like acute leukemia. It may help your body rebuild a healthier immune system after high-dose treatment.
Minneapolis, MinnesotaAges Up to 60 years - NCT04972942RecruitingPhase 1
Immunotherapy for high-risk T-cell blood cancers after transplant
This Phase 1 study tests a targeted immune treatment given after strong pre-treatment (myeloablative chemo plus total-body radiation) before or along with an allogeneic stem cell transplant. It may help prevent the cancer from coming back in young people with high-risk T-cell ALL or certain T-cell lymphomas.
Phoeniz, ArizonaAges Up to 39 years - NCT05014165Recruiting
Cord blood study for leukemia with stored birth samples
This study looks at leukemia “genetic clues” using special stored samples, including cord blood saved at birth. It may help researchers better understand leukemia biology and how common mutations may show up early.
Minneapolis, MinnesotaAges Up to 25 years - NCT05029531RecruitingPhase 3
Immuno-chemotherapy for infants with B-lineage ALL
This trial tests a combination of medicines (immunotherapy plus chemotherapy) in babies diagnosed with a type of leukemia called B-lineage acute lymphoblastic leukemia (ALL). It aims to improve how well treatment works and is delivered safely in very young children.
Moscow, Samory-Mashela,1Ages 1 day–12 months - NCT05031897RecruitingPhase 2
Haplo transplant with reduced donor mismatch and radiation
This trial tests a special bone marrow/stem cell transplant approach using a partially matched family donor, along with conditioning treatment that involves radiation. It aims to help treat certain blood cancers by replacing damaged blood-forming cells with new ones from the donor.
Philadephia, PennsylvaniaAges 18 years+ - NCT05038696RecruitingPhase 1
CAR T-cell treatment for hard-to-control B-ALL
This Phase 1 trial tests a personalized “CAR T” cell treatment for people with relapsed or treatment-resistant B-lymphoblastic leukemia (B-ALL). It may help the immune system find and kill leukemia cells, especially when leukemia has not responded to standard treatment.
SingaporeAges 6 months–80 years - NCT05043571RecruitingPhase 1
CAR T-cell therapy for relapsed T-cell leukemia
This early-phase trial tests a lab-made immune cell treatment (CAR T-cells) aimed at T-cell leukemia that has come back or did not respond. It may help by targeting leukemia cells with a specific marker (CD7), especially in patients who failed standard treatment.
SingaporeAges 6 months–65 years - NCT05054257RecruitingPhase 1
CAR T19 for hard-to-treat blood cancers that have CD19
This Phase 1 study tests CAR T cells designed to attack cancer cells that carry a marker called CD19. It’s for adults with certain relapsed or treatment-resistant B-cell leukemias (ALL) or lymphomas (NHL) where other treatments may not have worked.
PragueAges 18–80 - NCT05210907RecruitingPhase 1
Hospital-made CD19 CAR-T for relapsed leukemia in children
This Phase 1 study tests a homemade (hospital-manufactured) immune treatment called CD19 CAR-T for children and teens with a type of leukemia that has come back or did not respond. It may help by targeting leukemia cells that carry the CD19 marker.
SeoulAges birth–25 years - NCT05281809RecruitingPhase 2
CAR T-cell therapy made locally for B-cell blood cancers
This Phase 2 trial tests a locally manufactured CAR T-cell treatment for certain B-cell lymphomas and B-ALL that have limited treatment options left. It may help your immune system attack cancer cells that carry the CD19 marker, potentially as a bridge to transplant for some patients.
Pittsburgh, PennsylvaniaAges 18–79 - NCT05292664RecruitingPhase 1
Venetoclax trial for high-risk blood cancers in young patients
This Phase 1 study tests venetoclax to treat certain high-risk blood cancers in children, teens, or young adults. It is designed to see if the drug can work safely for patients whose disease has returned or did not respond to prior treatment.
San Francisco, CaliforniaAges 1–40 - NCT05310591RecruitingPhase 1/Phase 2
Study anti-PD1 treatment with Kymriah re-dosing for leukemia
This Phase 1/2 trial studies giving an anti-PD1 antibody (like pembrolizumab or nivolumab) along with a second Kymriah (tisagenlecleucel) infusion in children and young adults whose B-cell leukemia is coming back or their Kymriah effect has faded. It may help the new immune treatment work better after the first Kymriah.
BordeauxAges 1–25 - NCT05326919Recruiting
Study biobank for people newly diagnosed with certain blood cancers
This study follows people who are newly diagnosed (and haven’t been fully treated yet) with specific leukemia or related blood disorders to help researchers learn which treatments may work best. It may help by connecting you to a larger “precision medicine” patient group for future research.
BobignyAges Any age - NCT05333302RecruitingPhase 1
CAR-T treatment study for children and young adults with CD19 leukemia
This Phase 1 study tests a CAR-T cell treatment made to target CD19 in children and young adults whose leukemia or lymphoma has come back or did not respond to prior treatment. It aims to see how the treatment works and how safe it is in this age group.
Minsk, Minsk OblastAges 1–30 - NCT05334823RecruitingPhase 2
CAR T-cell treatment for CD19-positive relapsed leukemia in children
This Phase 2 trial tests pCAR-19B, a customized immune-cell treatment for children and teens with CD19-positive B-ALL that has come back or did not respond to standard therapy. If eligible, you would receive the cell infusion after cell collection and testing to make sure the leukemia cells have the right marker.
Beijing, Beijing MunicipalityAges 3–21 - NCT05418088RecruitingPhase 1
CAR T-cell therapy for hard-to-treat B-cell cancers
This Phase 1 study tests lab-made immune cells (CAR T-cells) that target CD19, CD20, and/or CD22 in people with certain relapsed or refractory B-cell cancers. It may help by attacking cancer cells that still carry these targets, but eligibility is very specific and includes prior treatments and health/lab requirements.
Columbus, OhioAges 2 years+ - NCT05442515RecruitingPhase 1/Phase 2
CAR T-cell treatment for hard-to-treat B-cell cancers in youth
This trial tests a personalized immune-cell therapy (CAR T cells) made to attack B-cell cancers that have come back or did not respond to prior treatment. It aims to see how well the treatment works and how safe it is in children and young adults.
Bethesda, MarylandAges 3–39
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for acute lymphoblastic leukemia?
- Yes. Clin2 currently lists 398 recruiting acute lymphoblastic leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a acute lymphoblastic leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a acute lymphoblastic leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.